Joshua Schiffman

Joshua Schiffman is pediatric oncologist, physician-scientist, CEO, co-founder, entrepreneur... and just a nice guy (or so he tells people).

[Joshua Schiffman @jdschiffman]

One more day to vote! Polling closes on Tuesday night. Let the Cancer Fund know what you think about Peel's medicine to beat pancreatic cancer: https://t.co/Ur07XirrGV

[Joshua Schiffman @jdschiffman]

Elephants are amazing, and it's great to be part of Peel Therapeutics to support the conservation and careful study of these incredible creatures! 🐘🐘🐘

https://t.co/VOrNyrS4Iy

[Joshua Schiffman @jdschiffman]

Come join us at BIO International for our panel to discuss the newest approaches to cancer therapy, Tuesday, June 17, 1:45 PM in Boston.

[Joshua Schiffman @jdschiffman]

Thank you to @BioHiveUtah for the great article highlighting @peel_tx and the team. Together we're introducing new medicines for cancer that are effective and safe for patients.

https://t.co/z3yYRL0P6U

[Peel Therapeutics, Inc. @peel_tx]

https://t.co/KuATnQc3uz

[Peel Therapeutics, Inc. @peel_tx]

Excited for Children's Hospital of Philadelphia (CHOP) and their patients who now have access to PEEL-224 through a new CHOP-sponsored clinical trial. Amazing to reach this pediatric milestone in PEEL-224 development, a drug originally developed at CHOP.

https://t.co/IsqyfCupii

[Joshua Schiffman @jdschiffman]

Excited to give closing talk this afternoon at the AACR WORKSHOP ON TRANSLATIONAL CANCER RESEARCH FOR BASIC SCIENTISTS. Thank you, @AACR , for this opportunity. Go evolutionary medicine! Go Peel Therapeutics!

[Joshua Schiffman @jdschiffman]

Fantastic article today in @DrugDiscovNews about our Darwin Discovery Platform, and how @peel_tx unlocks evolution for patients! Isn't evolution beautiful?

https://t.co/sFfI0htr26

[Peel Therapeutics, Inc. @peel_tx]

Great new article today by @luisatorresduq in @DrugDiscovNews about our Darwin Discovery Platform in Peel Therapeutics!

https://t.co/QEY2K6n740

[Peel Therapeutics, Inc. @peel_tx]

Great article this week in @BioWorld that describes @peel_tx and our best-in-class TOP1 inhibitor in Phase 1 clinical trial for advanced solid tumors. @peel_tx unlocks evolutionary biology to make new medicines for patients in need.
https://t.co/n4k5ORQXUm

[Joshua Schiffman @jdschiffman]

Congratulations to Dr. Avi Schroeder on his election as Fellow of AIMBE. Way to go, Avi!

https://t.co/ql5TJKCASc

[Peel Therapeutics, Inc. @peel_tx]

Amazing new paper about elephants and their cancer fighting p53 genes! Great example of how studying evolution gives new insights that could help future drug development. Elephants and their cancer resistance inspired the start of Peel Therapeutics!

https://t.co/KBe7BJFiRT

[Joshua Schiffman @jdschiffman]

It was an amazing adventure to deliver the Darwin Lecture in November at ICR in London! Thank you to my friend, mentor, host, and fellow Darwin aficionado, Professor Sir Mel Greaves.

#Darwin, #EvolutionaryMedicine, #icr, #peeltherapeutics

https://t.co/OuPmGd9hwO

[Peel Therapeutics, Inc. @peel_tx]

Thrilled that Peel Therapeutics won the 2023 People's Choice Award tonight at Altitude's Demo Day (https://t.co/RLiyPrVWRy), especially since the crowd also included high school students - some of the toughest critics! Big thanks to Peel team and @AltitudeLab! #BioHive, #BioUtah

[Peel Therapeutics, Inc. @peel_tx]

Today we announced the initiation of our first-in-human clinical study of PEEL-224 in patients with advanced solid tumors, following the recent acceptance of our Investigational New Drug Application by the U.S. Food and Drug Administration. Read more here: https://t.co/yhSX6fjsJx

[Peel Therapeutics, Inc. @peel_tx]

Excited to read this article in Utah Business Magazine! Our Peel team continues around the clock to make the evolutionary revolutionary! #PeelTherapeutics, #EvolutionaryMedicine, #Elephants

https://t.co/jhDTjItcWC

[Joshua Schiffman @jdschiffman]

@PeterZFedak @pachyderminc @lizfedakmath This is AMAZING !!!! Thank you for making this! Go elephants!

[Peter Fedak @PeterZFedak]

My @pachyderminc claymation entry (with help from @lizfedakmath), an allegory for p53 research at @jdschiffman lab

[JAMA Oncology @JAMAOnc]

Researchers identify a new poor prognostic marker in childhood leukemia. Across 6 cohorts of 1,310 pediatric B-ALL patients, combined focal 22q11.22 deletion + IKZF1 alteration predicts 43% event-free survival (EFS) vs 69% EFS for IKZF1 alteration alone https://t.co/x2guOR9efB

[International Journal of Cancer @IntJCanc]

NOW ONLINE | New study by Logan Spector, @Aubshub, et al

Authors used data from the #Cancer #Incidence in Five
Continents database to describe trends in #EwingSarcoma incidence across time, geographic regions & race/ethnicity

Read it here!
➡️https://t.co/tuLdS4FpQq

@UMNews